At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NVCR NovoCure
Market Closed 10-23 16:00:00 EDT
14.68
-0.42
-2.78%
盘后14.68
+0.000.00%
19:50 EDT
High14.97Low14.53Vol1.13M
Open14.85D1 Closing15.10Amplitude2.91%
Mkt Cap1.71BTradable Cap1.42BTotal Shares116.45M
T/O16.55MT/O Rate1.17%Tradable Shares96.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: NovoCure this quarter’s revenue is expected to increase by 14.48%, and institutional views are neutral
Earnings Agent  ·  10-22
Earning Preview: NovoCure this quarter’s revenue is expected to increase by 14.48%, and institutional views are neutral
Novocure receives approval for Optune Pax in Japan
TIPRANKS  ·  10-01
Novocure receives approval for Optune Pax in Japan
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
THOMSON REUTERS  ·  10-01
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Novocure to Report Q3 2026 Financial Results, Host Conference Call and Webcast
Reuters  ·  10-01
Novocure to Report Q3 2026 Financial Results, Host Conference Call and Webcast
Novocure to Report Third Quarter 2026 Financial Results
THOMSON REUTERS  ·  10-01
Novocure to Report Third Quarter 2026 Financial Results
US Companies Face Rise in Cyber Attacks
Reuters  ·  09-23
US Companies Face Rise in Cyber Attacks
Novocure Director Timothy Scannell Retires from Board
Reuters  ·  09-09
Novocure Director Timothy Scannell Retires from Board
NovoCure’s PANOVA-4 Trial Hits Completion, Raising New Questions for Pancreatic Cancer Investors
TIPRANKS  ·  09-05
NovoCure’s PANOVA-4 Trial Hits Completion, Raising New Questions for Pancreatic Cancer Investors
Novocure CEO to Speak at Wells Fargo Healthcare Conference
Reuters  ·  09-02
Novocure CEO to Speak at Wells Fargo Healthcare Conference
Novocure Announces Upcoming Investor Events
THOMSON REUTERS  ·  09-02
Novocure Announces Upcoming Investor Events
Oncology Firm Novocure Says Cyberattack Exposed US Patient Records
Reuters  ·  09-01
Oncology Firm Novocure Says Cyberattack Exposed US Patient Records
Novocure aware of unauthorized access to some information systems
TIPRANKS  ·  09-01
Novocure aware of unauthorized access to some information systems
Novocure Limited: Do not Believe Incident Will Have Material Impact or Likely Material Impact on Financial Condition & Results of Operations
THOMSON REUTERS  ·  09-01
Novocure Limited: Do not Believe Incident Will Have Material Impact or Likely Material Impact on Financial Condition & Results of Operations
Novocure - no Access to Medical Devices Obtained; Operations and Systems Fully Functional - SEC Filing
THOMSON REUTERS  ·  09-01
Novocure - no Access to Medical Devices Obtained; Operations and Systems Fully Functional - SEC Filing
Novocure - Reports Unauthorized Access to Information Systems in Mid-August 2026 - SEC Filing
THOMSON REUTERS  ·  09-01
Novocure - Reports Unauthorized Access to Information Systems in Mid-August 2026 - SEC Filing
Novocure - Exposed Data Included Internal Patient ID Numbers for over 1,400 U.S. Records - SEC Filing
THOMSON REUTERS  ·  09-01
Novocure - Exposed Data Included Internal Patient ID Numbers for over 1,400 U.S. Records - SEC Filing
Novocure - General Contact Information for Providers and Employees was Exposed - SEC Filing
THOMSON REUTERS  ·  09-01
Novocure - General Contact Information for Providers and Employees was Exposed - SEC Filing
Novocure Investigates Unauthorized Access to Some Information Systems
Reuters  ·  09-01
Novocure Investigates Unauthorized Access to Some Information Systems
Is NovoCure (NVCR) A Bargain On Rising Earnings Estimates?
Simply Wall St.  ·  08-30
Is NovoCure (NVCR) A Bargain On Rising Earnings Estimates?
Should NovoCure’s (NVCR) Upgraded Momentum Score and Earnings Revisions Require Action From Investors?
Simply Wall St.  ·  08-22
Should NovoCure’s (NVCR) Upgraded Momentum Score and Earnings Revisions Require Action From Investors?
No data available

Introduction

Company Name.
NovoCure
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Issue price:
--